[Intravenous verapamil in hypertrophic myocardiopathy. A study using Doppler ultrasound].
The effect of one intravenous dose of verapamil on left ventricular diastolic and systolic flow was studied by Doppler-echocardiography in 31 patients with hypertrophic cardiomyopathy. On diastolic flow, verapamil induced a decrease in "a" wave velocity (1.02 + 0.37 vs 0.91 + 0.29 m/seg, p less than 0.01), and in its relation with maximal protodiastolic velocity (1.08 + 0.56 vs 0.89 + 0.37, p less than 0.01), and a shortening in the isovolumic relaxation period (0.076 + 0.031 vs 0.068 + 0.02, p less than 0.05). On the ejection flow, verapamil decreased the peak velocity (2.82 + 1.28 vs 2.42 + 1.18 m/seg, p less than 0.001). Nor age, sex, ventricular mass, gradient, neither hypertrophic cardiomyopathy's classification relates with changes after intravenous verapamil. There were no adverse effects. This study by Doppler-echocardiography confirms the beneficial ++ effect of intravenous verapamil in patients with hypertrophic cardiomyopathy not only on gradient reduction but also in the improvement on left ventricular diastolic function.
de la Morena Valenzuela
G
G
Unidad de Cardiología-Hemodinámica, Hospital Virgen de la Arrixaca, Murcia.
Ruipérez Abizanda
J A
JA
Picó Aracil
F
F
García García
J
J
Jaén Armand
E
E
Salas Nieto
J
J
D000293:Adolescent; D000328:Adult; D000368:Aged; D006332:Cardiomegaly / Q000188:drug therapy* / Q000503:physiopathology; D002648:Child; D004341:Drug Evaluation; D015150:Echocardiography, Doppler; D005260:Female; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D008875:Middle Aged; D013318:Stroke Volume / Q000187:drug effects; D014700:Verapamil / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*
D014700:Verapamil
Verapamil intravenoso en la miocardiopatía hipertrófica. Estudio mediante ultrasonidos-Doppler.